Reference number of the aid programme: SA.41471(2015/X) Purpose of public aid: Article 25 of EC Regulation No 651/2014 of 17 June 2014 declaring certain types of aid compatible with the internal market in the application of Articles 107 and 108 of the Treaty (OJ L. I'm sorry. EU L 187/1 of 26.06.2014). As a result of an ageing population and the impact of environmental factors, the share of mortality caused by oncological diseases increases. Despite the progress of basic research and the development of new treatment strategies, many types of cancer remain incurable. One of the features of cancer cells is the altered metabolism, which must meet the increased energy demand and anabolic cancer. Many of the first generations of chemotherapeutic agents are antimetabolites, i.e. molecules that block key metabolic processes of cancer cells using a strong structural similarity to natural cell substrates. Despite the efficacy confirmed by clinical practice, antimetabolites are characterised by a number of significant drawbacks due to the lack of selectivity and side effects. The aim of the project will be to inhibit the metabolism of serine and the cycle of folic acid, using small-molecule inhibitors with a confirmed selective mechanism of action. The development of the research allowed to identify key node points of metabolism, protein molecular targets and markers of sensitivity and selection of patients. Based on this knowledge, new active molecules will be designed and developed, enabling a targeted therapeutic approach. In addition to the greater effectiveness of personalised pharmacotherapy, these molecules will have a high safety of use thanks to the specificity of the action. The molecular targets selected in the project offer a good chance of getting the first drug in their class. first-in-class).